A. Zdeněk

A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients

M. Boccadoro, R. Hájek, A. Larocca, 2013 .

Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration

A. Zdeněk, Pour Ludek, Svachova Hana, 2010, European journal of haematology.

Skin lesions induced by bortezomib.

R. Hájek, J. Vorlíc̆ek, L. Pour, 2005, Haematologica.

A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

M. Boccadoro, D. Rossi, R. Hájek, 2013 .

A147 Thalidomide/Interferon Versus Interferon Maintenance After Thal/Dex Versus MP

A. Hinke, R. Hájek, H. Gisslinger, 2009 .